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Dear Editor,
Recently, we read an article entitled “Inhibition of PI3K/Akt sig-
naling suppresses epithelial-to-mesenchymal transition in hepato-
cellular carcinoma through the Snail/GSK-3/beta-catenin path-
way” by Lee et al.1 with profound interest. The study showed that 
phosphoinositide 3-kinase (PI3K) inhibitors, LY294002 and Idelal-
isib, restrict epithelial-to-mesenchymal transition as indicated by 
upregulation of E-cadherin and downregulation of N-cadherin. 
Furthermore, PI3K inhibitors were reported to induce nuclear 
translocation of GSK-3β that was shown to decrease the expres-
sion of Snail and β-catenin in HepG2 and Huh-BAT cells. Subse-
quently, PI3K inhibitors were reported to supress the proliferation 
and invasion of hepatocellular carcinoma (HCC). However, before 
interpreting the results of the published study, several concerns 
should be taken into consideration.
At first, class I PI3K signaling has been known to be crucial for 
HCC progression, and thereby, substitutes as a therapeutic target 
for the treatment of HCC. Furthermore, PI3K has three catalytic 
subunits, which includes PI3K-α, PI3K-β, PI3K-δ.2 Several studies 
have reported that upregulation of PI3Kδ is positively correlated 
with progression of human advanced cancers such as HCC and 
melanoma.3,4 Moreover, Idelalisib is well-known as a first-in-class 
PI3Kδ inhibitor for the treatment of leukemia.5 Recently, it has 
been reported that Idelalisib suppresses HCC progression.4 Subse-
quently, high expression levels of PI3Kδ have been associated 
with advanced HCC.4 However, PI3Kδ expression levels in Huh7-
BAT and HepG2 cell lines have not been shown in this study. It is 
crucial to elucidate the effects of PI3Kδ inhibitor on HCC progres-
sion.
Secondly, it is well-known that LY294002 inhibits PI3K/AKT/
mammalian target of rapamycin complex 1 (mTORC1) pathway.6 
In several cancers, this has been reported to cause significant re-
duction in the capability of cancer cells pertaining to viability, mi-
gration, and invasion.7,8 However, AKT phosphorlation has been 
shown to be upregulated in LY294002-treated Huh-BAT cells. 
Thus, attributes of Huh-BAT cells need to be elucidated. Further-
more, the detailed mechanisms of LY294002 that lead to inhibi-
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tion of PI3K/AKT/mTORC1 pathway in HCC cell lines are not yet 
evident. Subsequently, the mechanism needs to be further vali-
dated.
Furthermore, diverse roles of serine/threonine kinase glycogen 
synthase kinase 3 (GSK3β) in cancer progression still remain con-
troversial.6 However, several studies have reported that GSK3β 
acts as a tumor suppressor gene, and thereby, it has been sug-
gested to be a promising therapeutic target for HCC treatment.9-11 
Additionally, GSK3β has been associated with signaling pathways 
such as Notch-, Wnt/β-catenin-, and transforming growth factor 
(TGF) β-pathway, that have been implicated in HCC pathogene-
sis.12 However, the detailed interactive mechanisms of GSK3β and 
PI3K inhibitors are not elucidated. This study showed that PI3K in-
hibitors upregulate the expression of nuclear GSK3β, which fur-
ther suppresses snail expression in liver cancer cell lines.
In conclusion, Lee et al.’s study1 provides the anti-cancer effects 
and comprehensive mechanisms of PI3K inhibitors in HCC cell 
lines. It suggests that PI3K is a potential therapeutic target for the 
treatment of HCC.
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